miDiagnostics, which is using silicon chip technology that will bring miniaturised, lab-quality tests with built-in connectivity direct to the patient and clinician regardless of location, has completed a €14 million investment round.
The round was supported by existing shareholders as well as life science and tech investors Dr. Rudi Pauwels and Dr. Ir. Urbain Vandeurzen.
The funds will be used to accelerate the development of miDiagnostics’ nanofluidic processor on a chip, and to prepare it for industrial-scale manufacturing. miDiagnostics’ technology aims to enable fast, comprehensive and cost-effective analysis of a wide range of health conditions. The technology has potential in multiple settings:
- Monitoring chronic patients at home;
- Screening for physicians or remote health centres in developing countries; and
- Widespread monitoring during pandemics
Dr. Rudi Pauwels, chairman of miDiagnostics, said: “Since joining the Board of Directors in 2018, I’ve been impressed by the rapid technical progress of miDiagnostics’ proprietary nano-fluidic processor on a chip and its real disruptive potential in the global diagnostics market. I’ve been actively working with the excellent team at miDiagnostics to accelerate commercialisation.”
miDiagnostics’ technology was invented by imec, the R&D and innovation hub in nanoelectronics and digital technologies in Belgium, and Johns Hopkins University, the US research and medical centre.
miDiagnostics is currently working with NASA to evaluate its technology under simulated zero gravity conditions.
Dr. Ir. Urbain Vandeurzen, a serial entrepreneur and founder and chairman of Smile Invest and former co-founder, chairman and CEO of LMS International, participated through his family office VMF Invest, which has made a number of investments in fast growing technology and life sciences companies. LMS International was sold to Siemens in 2013 and is the most successful technology spin-out of KU Leuven University.
Dr. Rudi Pauwels and Dr. Ir. Urbain Vandeurzen join the existing investors and entrepreneurs Marc Coucke (Alychlo) and Michel Akkermans (Pamica) as well as PMV (the investment fund of the Flanders Region) and the technology founders imec and Johns Hopkins University.
Nicolas Vergauwe, chief executive officer of miDiagnostics, said: “The continued commitment of our founding partners imec and JHU, our existing shareholders and this latest endorsement by two highly successful serial entrepreneurs further strengthens our confidence in the future of miDiagnostics. They share our view that miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information as readily accessible as digital information on a smartphone. Together with the recent progress in advancing our technology and bringing in the right expertise on board to deliver commercial success, we are well placed to make rapid progress.”
